No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
0.5% marcaine |
- |
- |
- |
- |
1件: 70 |
2 |
0.9% saline |
- |
- |
- |
- |
1件: 70 |
3 |
0002-8971 |
- |
- |
- |
- |
1件: 70 |
4 |
1mg/kg/hr txa intravenous infusion till the last suture |
- |
- |
- |
- |
1件: 70 |
5 |
Acetaminophen |
Acetaminophen |
D00217 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
11件: 13, 34, 35, 46, 49, 51, 70, 86, 231, 256, 271 |
6 |
Acetate |
Acetate |
- |
- |
- |
40件: 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
7 |
Allogen-li |
- |
- |
- |
- |
1件: 70 |
8 |
Alprostadil |
Alprostadil |
D00180, D02705 |
1件: PTGER1 |
4件: Calcium signaling pathway, Human cytomegalovirus infection, Neuroactive ligand-receptor interaction, Pathways in cancer |
2件: 51, 70 |
9 |
Amino acids |
Amino acids |
- |
- |
- |
4件: 70, 90, 240, 298 |
10 |
Aminocaproic acid |
Aminocaproic acid |
D00160 |
1件: PLG |
4件: Complement and coagulation cascades, Influenza A, Neuroactive ligand-receptor interaction, Staphylococcus aureus infection |
1件: 70 |
11 |
Bilateral transforaminal epidural steroid injections |
- |
- |
- |
- |
1件: 70 |
12 |
Botulinum toxin type a |
Botulinum toxin type a |
D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
10件: 2, 5, 6, 7, 13, 15, 17, 70, 113, 149 |
13 |
Botulinum toxin type a (nabota®) injection into the gastrocnemius muscle |
Botulinum toxin type a |
D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
1件: 70 |
14 |
Bupivacaine |
Bupivacaine |
D01450, D07552 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
7件: 46, 53, 70, 96, 168, 226, 298 |
15 |
Buprenorphine |
Buprenorphine |
D00836, D07132 |
2件: OPRK1, OPRM1 |
3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
2件: 46, 70 |
16 |
Caudal epidural injection |
- |
- |
- |
- |
1件: 70 |
17 |
Caudal epidural injection with celestone |
- |
- |
- |
- |
1件: 70 |
18 |
Caudal epidural injection with depomedrol |
- |
- |
- |
- |
1件: 70 |
19 |
Caudal epidural injection with generic celestone |
- |
- |
- |
- |
1件: 70 |
20 |
Celebrex 200mg capsule |
- |
- |
- |
- |
1件: 70 |
21 |
Celecoxib |
Celecoxib |
D00567 |
1件: PTGS2 |
20件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
8件: 2, 3, 34, 46, 70, 89, 161, 271 |
22 |
Cilostazol |
Cilostazol |
D01896 |
3件: PDE3A, PDE3B, TBXA2R |
14件: Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Platelet activation, Progesterone-mediated oocyte maturation, Purine metabolism, Regulation of lipolysis in adipocytes, Renin secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
2件: 51, 70 |
23 |
Control group |
- |
- |
- |
- |
2件: 46, 70 |
24 |
Darvocet |
- |
- |
- |
- |
1件: 70 |
25 |
Decadron phosphate, injectable |
Phosphate ion |
- |
- |
- |
1件: 70 |
26 |
Deksmedetomidiini |
- |
- |
- |
- |
1件: 70 |
27 |
Demineralized bone matrix |
- |
- |
- |
- |
1件: 70 |
28 |
Depomedrol |
- |
- |
- |
- |
1件: 70 |
29 |
Dexamethasone |
Dexamethasone |
D00292, D00975, D01510, D01615, D01632, D01948, D02174, D02591, D02592 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
20件: 13, 16, 28, 35, 46, 53, 63, 65, 70, 74, 75, 81, 83, 84, 90, 96, 97, 222, 296, 299 |
30 |
Dexdor |
- |
- |
- |
- |
4件: 2, 4, 6, 70 |
31 |
Dexmedetomidine |
Dexmedetomidine |
D00514, D01205 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
11件: 2, 4, 6, 21, 34, 70, 113, 212, 215, 226, 280 |
32 |
Dexmedetomidine group |
Dexmedetomidine |
D00514, D01205 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
1件: 70 |
33 |
Dexmedetomidine hydrochloride |
Dexmedetomidine |
D00514, D01205 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
1件: 70 |
34 |
Diphenhydramine |
Diphenhydramine |
D00300, D00669, D02419, D03285, D03360, D03854 |
1件: HRH1 |
3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
5件: 49, 51, 70, 86, 256 |
35 |
Eaca |
Aminocaproic acid |
D00160 |
1件: PLG |
4件: Complement and coagulation cascades, Influenza A, Neuroactive ligand-receptor interaction, Staphylococcus aureus infection |
1件: 70 |
36 |
Epidural injection |
- |
- |
- |
- |
1件: 70 |
37 |
Epidural local anesthetic injection |
- |
- |
- |
- |
1件: 70 |
38 |
Epidural steroid injection |
- |
- |
- |
- |
1件: 70 |
39 |
Epsilon-aminocaproic acid (eaca) |
Aminocaproic acid |
D00160 |
1件: PLG |
4件: Complement and coagulation cascades, Influenza A, Neuroactive ligand-receptor interaction, Staphylococcus aureus infection |
1件: 70 |
40 |
Erythropoietin |
Erythropoietin |
D03231 |
1件: EPOR |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
8件: 2, 6, 13, 22, 47, 70, 95, 96 |
41 |
Esketamine |
Esketamine |
D07283 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
3件: 2, 4, 70 |
42 |
Esketamine hydrochloride |
Esketamine |
D07283 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 70 |
43 |
Fentanyl |
Fentanyl |
D00320, D01399 |
1件: OPRM1 |
3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
5件: 46, 70, 85, 215, 231 |
44 |
Forsteo |
- |
- |
- |
- |
3件: 70, 235, 274 |
45 |
Forteo |
Teriparatide |
D06078 |
1件: PTH1R |
3件: Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action |
1件: 70 |
46 |
Gabapentin |
Gabapentin |
D00332 |
5件: CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 |
9件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cardiac muscle contraction, Dilated cardiomyopathy (DCM), GABAergic synapse, Hypertrophic cardiomyopathy (HCM), MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle |
5件: 6, 13, 19, 70, 298 |
47 |
Heparin |
Heparin |
D07510 |
1件: SERPINC1 |
1件: Complement and coagulation cascades |
11件: 60, 70, 79, 84, 107, 224, 226, 280, 299, 316, 317 |
48 |
Herbal medicine |
- |
- |
- |
- |
1件: 70 |
49 |
Hyaluronic acid |
Hyaluronic acid |
D08043 |
- |
- |
5件: 46, 53, 70, 226, 231 |
50 |
I-factor |
- |
- |
- |
- |
1件: 70 |
51 |
Kenalog injectable product |
- |
- |
- |
- |
1件: 70 |
52 |
Ketamine |
Ketamine |
D00711, D08098 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
5件: 13, 70, 113, 156, 215 |
53 |
Ketanest-s |
- |
- |
- |
- |
3件: 2, 4, 70 |
54 |
Ketorolac |
Ketorolac |
D00813, D08104 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
2件: 70, 226 |
55 |
Limaprost |
Limaprost |
D02722 |
1件: PTGER1 |
4件: Calcium signaling pathway, Human cytomegalovirus infection, Neuroactive ligand-receptor interaction, Pathways in cancer |
1件: 70 |
56 |
Liposomal bupivacaine |
Bupivacaine |
D01450, D07552 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
2件: 70, 96 |
57 |
Lumbar interbody fusion with autograft |
- |
- |
- |
- |
1件: 70 |
58 |
Lumbar interbody fusion with neofuse |
- |
- |
- |
- |
1件: 70 |
59 |
Midazolam |
Midazolam |
D00550, D00696, D05028 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
10件: 2, 3, 6, 13, 46, 70, 96, 97, 231, 298 |
60 |
Monitor |
Methamidophos |
- |
- |
- |
12件: 2, 11, 13, 19, 46, 49, 58, 70, 85, 98, 298, 300 |
61 |
Morphine |
Morphine |
D00842, D02271, D08233 |
1件: OPRM1 |
3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
4件: 36, 46, 70, 86 |
62 |
Morphine pca |
Morphine |
D00842, D02271, D08233 |
1件: OPRM1 |
3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
1件: 70 |
63 |
Neofuse |
- |
- |
- |
- |
1件: 70 |
64 |
Nicardipine |
Nicardipine |
D00617, D08270 |
4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S |
34件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
2件: 70, 86 |
65 |
Ns-304 |
- |
- |
- |
- |
3件: 70, 86, 88 |
66 |
Ns-304 placebo |
- |
- |
- |
- |
2件: 70, 88 |
67 |
Nsaids |
- |
- |
- |
- |
4件: 46, 70, 107, 271 |
68 |
Nucel |
- |
- |
- |
- |
1件: 70 |
69 |
Nucel with autograft |
- |
- |
- |
- |
1件: 70 |
70 |
Oksikodoni |
- |
- |
- |
- |
1件: 70 |
71 |
Opana |
Oxymorphone |
D08323 |
1件: OPRM1 |
3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
1件: 70 |
72 |
Oxanest |
- |
- |
- |
- |
1件: 70 |
73 |
Oxycodone |
Oxycodone |
D03783, D05312, D05462 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
7件: 6, 13, 46, 70, 226, 231, 298 |
74 |
Oxycodone hydrochloride |
Oxycodone |
D03783, D05312, D05462 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
3件: 70, 226, 298 |
75 |
Oxycodone orion |
Oxycodone |
D03783, D05312, D05462 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
1件: 70 |
76 |
Oxygen |
Oxygen |
D00003 |
- |
- |
14件: 46, 49, 70, 84, 85, 86, 88, 90, 96, 97, 193, 226, 299, 330 |
77 |
Parathyroid hormone |
Parathyroid hormone |
D05364 |
2件: PTH1R, PTH2R |
3件: Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action |
2件: 70, 235 |
78 |
Phosphate |
Phosphate ion |
- |
- |
- |
29件: 2, 3, 11, 12, 13, 28, 36, 46, 49, 51, 53, 60, 62, 65, 70, 78, 81, 83, 90, 96, 97, 164, 235, 256, 283, 284, 285, 286, 299 |
79 |
Predinose oral |
- |
- |
- |
- |
1件: 70 |
80 |
Pregabalin |
Pregabalin |
D02716 |
4件: CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4 |
7件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cardiac muscle contraction, Dilated cardiomyopathy (DCM), Hypertrophic cardiomyopathy (HCM), MAPK signaling pathway, Oxytocin signaling pathway |
5件: 13, 36, 46, 70, 298 |
81 |
Pregabalin 75mg |
Pregabalin |
D02716 |
4件: CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4 |
7件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cardiac muscle contraction, Dilated cardiomyopathy (DCM), Hypertrophic cardiomyopathy (HCM), MAPK signaling pathway, Oxytocin signaling pathway |
1件: 70 |
82 |
Prolotherapy solution of 20% dextrose |
- |
- |
- |
- |
1件: 70 |
83 |
Remifentanil |
Remifentanil |
D01177, D08473 |
1件: OPRM1 |
3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
2件: 6, 70 |
84 |
Rhpth |
Parathyroid hormone |
D05364 |
2件: PTH1R, PTH2R |
3件: Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action |
3件: 70, 235, 326 |
85 |
Rhpth (1-34) |
Parathyroid hormone |
D05364 |
2件: PTH1R, PTH2R |
3件: Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action |
1件: 70 |
86 |
Ropivacaine |
Ropivacaine |
D04048, D08490 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
3件: 36, 46, 70 |
87 |
S-ketamine |
Ketamine |
D00711, D08098 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 70 |
88 |
S-ketamine & midazolam |
Midazolam |
D00550, D00696, D05028 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
1件: 70 |
89 |
Selexipag |
Selexipag |
D09994 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
5件: 51, 70, 84, 86, 88 |
90 |
Sugar pill |
- |
- |
- |
- |
7件: 6, 49, 67, 70, 86, 206, 226 |
91 |
Teriparatide |
Teriparatide |
D06078 |
1件: PTH1R |
3件: Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action |
6件: 46, 68, 70, 71, 235, 274 |
92 |
Teriparatide [rdna origin] contains recombinant human parathyroid hormone (1-34) |
Parathyroid hormone |
D05364 |
2件: PTH1R, PTH2R |
3件: Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action |
1件: 70 |
93 |
Titanium |
Titanium |
- |
- |
- |
2件: 69, 70 |
94 |
Tramadol |
Tramadol |
D01355, D08623 |
1件: OPRM1 |
3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
5件: 46, 70, 78, 226, 271 |
95 |
Tranexamic acid |
Tranexamic acid |
D01136 |
1件: PLG |
4件: Complement and coagulation cascades, Influenza A, Neuroactive ligand-receptor interaction, Staphylococcus aureus infection |
5件: 46, 70, 215, 227, 288 |
96 |
Tranexamic acid 100 mg/ml |
Tranexamic acid |
D01136 |
1件: PLG |
4件: Complement and coagulation cascades, Influenza A, Neuroactive ligand-receptor interaction, Staphylococcus aureus infection |
1件: 70 |
97 |
Transdermal fentanyl matrix, gabapentin |
Gabapentin |
D00332 |
5件: CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 |
9件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cardiac muscle contraction, Dilated cardiomyopathy (DCM), GABAergic synapse, Hypertrophic cardiomyopathy (HCM), MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle |
1件: 70 |
98 |
Triamcinolone |
Triamcinolone |
D00385, D00983, D00984, D00985, D06216 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
8件: 35, 46, 56, 70, 90, 96, 226, 298 |
99 |
Triamcinolone acetonide and normal saline solution |
Triamcinolone |
D00385, D00983, D00984, D00985, D06216 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 70 |
100 |
Vancomycin |
Vancomycin |
D00212, D00926 |
- |
- |
7件: 46, 70, 94, 96, 97, 296, 299 |
101 |
Vivigen cellular bone matrix |
- |
- |
- |
- |
1件: 70 |
102 |
With u-vanco (vancomycin hydrochloride) |
Vancomycin |
D00212, D00926 |
- |
- |
1件: 70 |
103 |
Without u-vanco (vancomycin hydrochloride) |
Vancomycin |
D00212, D00926 |
- |
- |
1件: 70 |
104 |
Wound topically irrigated with 500mg txa |
- |
- |
- |
- |
1件: 70 |